Ferdinand Verdonck
President chez Dellacorte Acquisition Corp.
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Harry Welten | M | 59 |
Affimed GmbH
 Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 4 ans |
| Ulrich Grau | M | 75 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 9 ans |
| Matt Kapusta | M | 51 | 9 ans | |
| Bernhard R. M. Ehmer | M | 69 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 8 ans |
| Wolfgang Fischer | M | 60 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 7 ans |
| Christian Klemt | M | 51 | 9 ans | |
| Paula Soteropoulos | F | 56 | 11 ans | |
| Mathieu Simon | M | 68 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 6 ans |
| Annalisa Jenkins | M | 58 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 4 ans |
| Andreas Harstrick | M | 63 | 4 ans | |
| Robert F. Mancuso | M | 78 |
Dellacorte Acquisition Corp.
 Dellacorte Acquisition Corp. MiscellaneousMiscellaneous Dellacorte Acquisition Corp. operates as a blank check company. It is a development stage company and serves as a vehicle to effect a merger, exchange of capital stock, and asset acquisition. The company was founded on October 17, 2007 and is headquartered in New York, NY. | - |
| Jack Kaye | M | 80 | 8 ans | |
| Leroy Keith | M | 85 |
The Phoenix Funds
| - |
| Adolf Hoess | M | 62 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 14 ans |
| Susanne Hering | F | - | 9 ans | |
| Thomas O. Hecht | M | 73 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 17 ans |
| Alexander Fudukidis | M | - | 4 ans | |
| Denise Mueller | F | 55 | 8 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Philip Astley-Sparke | M | 51 | 8 ans | |
| David Schaffer | M | 53 | 6 ans | |
| Jörn Aldag | M | 65 | 6 ans | |
| Andrew John Adcock | M | 70 |
JPMorgan European Investment Trust Plc Growth Shares
 JPMorgan European Investment Trust Plc Growth Shares Investment Trusts/Mutual FundsMiscellaneous JPMorgan European Investment Trust Plc Growth Shares is a closed-end investment trust. It engages in the provision of capital growth from European investments and a rising share price over the longer term. The company was founded in 1929 and is headquartered in London, the United Kingdom. | - |
| Joseph Feczko | M | 75 | 4 ans | |
| Howard Mitchell Rowe | M | 55 | 12 ans | |
| Rudi Pauwels | M | 65 | 11 ans | |
| Will Lewis | M | 55 | - | |
| Vicki Sato | M | 75 | 3 ans | |
| Jutta af Rosenborg | F | 65 |
JPMorgan European Investment Trust Plc Growth Shares
JPMorgan European Investment Trust Plc Growth Shares Investment Trusts/Mutual FundsMiscellaneous JPMorgan European Investment Trust Plc Growth Shares is a closed-end investment trust. It engages in the provision of capital growth from European investments and a rising share price over the longer term. The company was founded in 1929 and is headquartered in London, the United Kingdom. | - |
| Dirk Heremans | M | 81 |
Almanij NV
| - |
| Philippe A. Naert | M | 81 |
Almanij NV
| - |
| Steve Russell | M | 60 |
JPMorgan European Investment Trust Plc Growth Shares
JPMorgan European Investment Trust Plc Growth Shares Investment Trusts/Mutual FundsMiscellaneous JPMorgan European Investment Trust Plc Growth Shares is a closed-end investment trust. It engages in the provision of capital growth from European investments and a rising share price over the longer term. The company was founded in 1929 and is headquartered in London, the United Kingdom. | - |
| Piet Wigerinck | M | 58 | 13 ans | |
| François Meyer | M | 76 | 4 ans | |
| Lieven Larmuseau | M | 62 | 35 ans | |
| Eva M. Mulder | F | - | 5 ans | |
| Anne Kerber | M | - | - | |
| Hugo Slootweg | M | 53 | 2 ans | |
| Robin Henry Grey Faber | M | 69 |
JPMorgan European Investment Trust Plc Growth Shares
JPMorgan European Investment Trust Plc Growth Shares Investment Trusts/Mutual FundsMiscellaneous JPMorgan European Investment Trust Plc Growth Shares is a closed-end investment trust. It engages in the provision of capital growth from European investments and a rising share price over the longer term. The company was founded in 1929 and is headquartered in London, the United Kingdom. | 14 ans |
| Harrold van Barlingen | M | 58 | 13 ans | |
| Stephen Goldman | M | - |
JPMorgan European Investment Trust Plc Growth Shares
JPMorgan European Investment Trust Plc Growth Shares Investment Trusts/Mutual FundsMiscellaneous JPMorgan European Investment Trust Plc Growth Shares is a closed-end investment trust. It engages in the provision of capital growth from European investments and a rising share price over the longer term. The company was founded in 1929 and is headquartered in London, the United Kingdom. | - |
| Andrew H. Murison | M | 75 |
JPMorgan European Investment Trust Plc Growth Shares
JPMorgan European Investment Trust Plc Growth Shares Investment Trusts/Mutual FundsMiscellaneous JPMorgan European Investment Trust Plc Growth Shares is a closed-end investment trust. It engages in the provision of capital growth from European investments and a rising share price over the longer term. The company was founded in 1929 and is headquartered in London, the United Kingdom. | 13 ans |
| Caroline Y. Stewart | F | - | - | |
| Josephine Dixon | F | 65 |
JPMorgan European Investment Trust Plc Growth Shares
JPMorgan European Investment Trust Plc Growth Shares Investment Trusts/Mutual FundsMiscellaneous JPMorgan European Investment Trust Plc Growth Shares is a closed-end investment trust. It engages in the provision of capital growth from European investments and a rising share price over the longer term. The company was founded in 1929 and is headquartered in London, the United Kingdom. | - |
| Werner Cautreels | M | 71 | - | |
| Piers John Morgan | M | 57 | 5 ans | |
| Florian Fischer | M | 56 | 15 ans | |
| Gregory W. Gin | M | - | - | |
| Don Soland | M | 65 | 1 ans | |
| Katrine Bosley | F | 56 | 9 ans | |
| Berndt A. E. Modig | M | 65 | 6 ans | |
| Geert Roelens | M | 69 | 23 ans | |
| Piet van Riet | M | 62 | - | |
| Michael Wolf | M | - | - | |
| Eric Goossens | M | 58 | 3 ans | |
| Efrat Konforty | F | - | - | |
| Oscar Kashala | M | - | - | |
| Ronald H. P. Brus | M | 61 | 11 ans | |
| Andrew Curtis | M | - | - | |
| Jöerg Windisch | M | 53 | 1 ans | |
| Leila Alland | M | 61 | 1 ans | |
| Wilson Totten | M | 68 | - | |
| Anca Alexandru | M | - | - | |
| Deya Corzo | M | 57 | 3 ans | |
| Angus Smith | M | 41 | 3 ans | |
| Yong Dai | M | 53 | 3 ans | |
| Radan Spaventi | M | - | - | |
| Martin Treder | M | - | 4 ans | |
| Andre Hoekema | M | 67 | 17 ans | |
| Christian Meyer | M | 56 | 4 ans | |
| Henry Geoffrey McMillan | M | - | - | |
| François M. de Visscher | M | 71 | 24 ans | |
| Laurent Gerard Ganem | M | 66 | - | |
| David Stone | M | - | - | |
| Edwin de Graaf | M | - | - | |
| Luc Philips | M | 73 |
Almanij NV
| - |
| Christopher Gregory Newton | M | 68 | 7 ans | |
| Paul Firuta | M | 58 | 2 ans | |
| Hans-Christian Rohde | M | 67 | - | |
| Leo Steenbergen | M | 71 | 2 ans | |
| Marcus Y. Smith | M | 57 |
JPMorgan European Investment Trust Plc Growth Shares
JPMorgan European Investment Trust Plc Growth Shares Investment Trusts/Mutual FundsMiscellaneous JPMorgan European Investment Trust Plc Growth Shares is a closed-end investment trust. It engages in the provision of capital growth from European investments and a rising share price over the longer term. The company was founded in 1929 and is headquartered in London, the United Kingdom. | 3 ans |
| Graham Dixon | M | 63 | 8 ans | |
| David Smith | M | 58 | 1 ans | |
| William Rapeport | M | - | - | |
| Theodoros Roussis | M | 70 |
Almanij NV
| 3 ans |
| Guillaume Jetten | M | 52 | 5 ans | |
| Arndt Justus Georg Schottelius | M | 58 | 4 ans | |
| Cassandra Choe-Juliak | M | - | - |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Belgique | 28 | 32,18% |
| Allemagne | 27 | 31,03% |
| Pays-Bas | 22 | 25,29% |
| Royaume-Uni | 8 | 9,20% |
| Etats-Unis | 2 | 2,30% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Ferdinand Verdonck
- Réseau Personnel
